SN-38内包高分子ミセルNK012日米独立 phase I 試験  [in Japanese] Two independent phase I trials of NK012, SN-38 incorporating micellar nanoparticle for patients with advanced cancer, opened in Japan and United States of America  [in Japanese]

Access this Article

Author(s)

Abstract

NK012は,CPT-11の活性体のSN-38を内包した高分子ミセル化製剤である.現在CPT-11は,幅広いがん腫に用いられているが,NK012はそのCPT-11と比較しSN-38の薬効を効率よく発現できると考えられている.日本とアメリカでそれぞれ独立したNK012の臨床第I相試験が行われ,その結果が報告された.<BR>これらの結果から,NK012の忍容性が確認され有用性が示唆された.次相からの試験において,そのDDS製剤としての特徴をはっきり証明することが期待されている.

NK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer;however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.<BR>It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.

Journal

  • Drug Delivery System

    Drug Delivery System 24(1), 54-61, 2009-01-23

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References:  14

Codes

  • NII Article ID (NAID)
    10024781144
  • NII NACSIS-CAT ID (NCID)
    AN10084591
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    09135006
  • NDL Article ID
    9797466
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-1945
  • Data Source
    CJP  NDL  J-STAGE 
Page Top